Newsroom

Industry News

5 Dec

Prima Biomed Enhances CVac Manufacturing and Logistics Capability

Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) (“Prima”, the “Company”) announces several enhancements to its CVac manufacturing and logistics infrastructure. Prima will be adopting a new apheresis system for collection of patient mononuclear cell products (“MNC”): the Spectra Optia Apheresis System (“Spectra Optia”) manufactured by US-based industry leader Terumo...

Read more

5 Dec

Cesca Therapeutics Appoints Mr. Denis Michael Rhein to Its Board of Directors

Cesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, today announced that Mr. Denis Michael Rhein (54) has been appointed to the Company’s Board of Directors. Mr. Rhein has over 30 years of corporate banking and securities experience at Deutsche Bank AG in Frankfurt, Germany. He served in...

Read more

5 Dec

Why Inovio Pharmaceuticals (INO) Stock Might be a Great Pick

One stock that might be an intriguing choice for investors right now is Inovio Pharmaceuticals, Inc. (INO). This is because this security in the medical space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often...

Read more

4 Dec

Lightlake Therapeutics Commences Trial For Treatment Of Opioid Overdose With The U.S. National Institute On Drug Abuse (NIDA)

Lightlake Therapeutics advances collaboration with NIDA for novel intranasal naloxone application to reverse opioid overdose Lightlake Therapeutics Inc. (“Lightlake”) (LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Lightlake has begun a trial designed to evaluate its intranasal naloxone application for...

Read more

2 Dec

ProActive Capital Group Announces Rebranding As PCG Advisory Group

New York, NY, December 2, 2014 – PCG Advisory Group (PCG) today announced its formal name change. After six years of operations and growth, the Company is changing its name to clearly reflect the significant expansion of its business services, which now include: capital markets advisory, investor relations, social...

Read more

2 Dec

Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray’s 26th Annual Healthcare Conference

Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today that CEO and President Linda Marban will deliver an overview of Capricor Therapeutics, Inc., to Piper Jaffray’s clients during a fireside chat session in the Rutherford Room of the...

Read more

2 Dec

Auryxia(TM) (Ferric Citrate) Phase 2 Data Published in the American Journal of Kidney Disease

Study Evaluated Auryxia in Non-Dialysis Dependent Chronic Kidney Disease (CKD) Patients Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced the publication of Auryxia phase 2 clinical trial results in non-dialysis dependent chronic kidney disease (NDD-CKD) patients...

Read more

Page 227 of 260« First...102030...225226227228229...240250260...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address